Firstly, anti-TNF therapy is contra-indicated in (RA) patients with CHF (New York Heart Association class III and IV) [18], following trials from the early ‘00s suggesting that anti-TNF possibly worsens CHF and increases mortality in non-RA patients with systolic CHF. The gene discussed is TNF; the disease is congestive heart failure.